Olema Pharmaceuticals, Inc.
OLMA
$10.63
$0.121.14%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 137.10% | 106.02% | 53.59% | 34.84% | -10.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 77.42% | 66.28% | 36.22% | 21.95% | 12.93% |
| Operating Income | -77.42% | -66.28% | -36.22% | -21.95% | -12.93% |
| Income Before Tax | -44.34% | -74.70% | -37.22% | -22.17% | -44.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.34% | -74.70% | -37.22% | -22.17% | -44.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.34% | -74.70% | -37.22% | -22.17% | -44.11% |
| EBIT | -77.42% | -66.28% | -36.22% | -21.95% | -12.93% |
| EBITDA | -77.77% | -66.55% | -36.14% | -22.14% | -12.85% |
| EPS Basic | -18.16% | -45.18% | 1.14% | 18.40% | 5.13% |
| Normalized Basic EPS | -53.12% | -45.21% | 1.13% | 18.40% | 26.79% |
| EPS Diluted | -18.16% | -45.18% | 1.14% | 18.40% | 5.13% |
| Normalized Diluted EPS | -53.12% | -45.21% | 1.13% | 18.40% | 26.79% |
| Average Basic Shares Outstanding | 22.17% | 20.34% | 38.79% | 49.72% | 51.91% |
| Average Diluted Shares Outstanding | 22.17% | 20.34% | 38.79% | 49.72% | 51.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |